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Background. Amyloid is insoluble aggregated proteins deposited in the extra cellular space. About 25 different proteins are
known to form amyloid in vivo and are associated with severe diseases such as Alzheimers disease, prion diseases and type-2
diabetes. Light chain (AL) -amyloidosis is unique among amyloid diseases in that the fibril protein, a monoclonal
immunoglobulin light chain, varies between individuals and that no two AL-proteins with identical primary structures have
been described to date. The variability in tissue distribution of amyloid deposits is considerably larger in systemic AL-
amyloidosis than in any other form of amyloidosis. The reason for this variation is believed to be based on the differences in
properties of the amyloidogenic immunoglobulin light chain. However, there is presently no known relationship between the
structure of an AL-protein and tissue distribution. Methodology/Principal Findings. We compared the pattern of amyloid
deposition in four individuals with amyloid protein derived from variable light chain gene O18-O8, the source of a high
proportion of amyloidogenic light chains, and in whom all or most of the fibril protein had been determined by amino acid
sequencing. In spite of great similarities between the structures of the proteins, there was a pronounced variability in
deposition pattern. We also compared the tissue distribution in these four individuals with that of four other patients with AL-
amyloid derived from the L2-L16 gene. Although the interindividual variations were pronounced, liver and kidney involvement
was much more evident in the latter four. Conclusions/Significance. We conclude that although the use of a specific gene
influences the tissue distribution of amyloid, each light chain exhibits one or more determinants of organ-specificity, which
originate from somatic mutations and post-translational modifications. Eventual identification of such determinants could lead
to improved treatment of patients with AL amyloidosis.
Citation: Enqvist S, Sletten K, Stevens FJ, Hellman U, Westermark P (2007) Germ Line Origin and Somatic Mutations Determine the Target Tissues in
Systemic AL-Amyloidosis. PLoS ONE 2(10): e981. doi:10.1371/journal.pone.0000981
INTRODUCTION
Amyloid is insoluble fibrillar protein deposited in the extracellular
space. The resulting heterogeneous group of disorders is called
amyloidosis. The protein in the fibrils are hydrogen bound
intermolecularly in b-sheets giving the fibrils a considerable
strength and the structure explains most of the characteristic
properties of amyloid. Today, about 25 proteins are known to
form amyloid in vivo and these are involved in life-threatening
disorders like type-2 diabetes and Creutzfeldt Jacobs disease [1].
The systemic amyloidoses are characterized by widely spread
deposits of specific proteins in a characteristic fibrillar form.
Usually vital organs are affected and the disorders are therefore
often lethal. More than ten different proteins are known to be able
to give rise to systemic amyloidosis, most of them in rare,
hereditary forms [1]. In systemic AL-amyloidosis, the amyloid
fibril protein is derived from monoclonal immunoglobulin light
chains. All light chain subtypes are capable of fibril formation
although lambda chains, particularly of lambda-VI type, are over-
represented.
The immunoglobulin light chain in systemic AL-amyloidosis is
produced by plasma cells, mainly in the bone marrow. The protein
is then circulating in plasma before it aggregates into the typical
amyloid fibrils at sites far from the origin. Most commonly it is not
the whole protein that is included but the variable region with
a part of the constant region. Whether or not this C-terminal
cleavage occurs before the assembly and is important in this
process or is a result of proteolytic trimming of a part not included
in the fibril core is still not known. Usually, full-length light chains
are included in the fibril as a minor component [2]. On rare
occasions, the major fibril protein is derived from the constant
region [3–5].
Systemic AL-amyloidosis is probably the most heterogeneous
form of amyloidosis that occurs. There is no general rule regarding
where deposits may occur, which is different from most other
systemic amyloidoses. Therefore, the clinical presentation is highly
variable. In some patients, cardiac symptoms predominate, in
others nephropathy. Again others present with polyneuropathy,
gastrointestinal disturbances, liver affection and so on [6]. In
accordance with the systemic nature of the disease, combinations
are common and in reality, most organs are involved also when
not giving symptoms. However, amyloid does not occur in the
central nervous system [7].
It has been difficult to explain why only some individuals with
production of monoclonal immunoglobulin light chains develop
systemic amyloidosis. After an increasing number of amino acid
sequences of AL-proteins have been obtained, it has become more
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chain subgroups [8] are over-represented in these proteins. In
addition, glycosylation may be linked to AL amyloidogenesis [9].
Further studies have given an increasing body of information on
the putative importance of certain amino acid substitutions in the
AL-protein sequences [10]. Thus, it was found that over 80% of
amyloidogenic kI variable light chains regions were characterized
by the presence of at least one of three single-site amino acid
substitutions or formation of an N-linked glycosylation site [10,11].
Consequently, it is increasingly clear that the most important risk
factor for the development of AL-amyloidosis is related to the
structure (and concentration) of the monoclonal immunoglobulin
light chain. Interestingly, at least for k chains, these risk factors
seem to be a random matter, since they may be identified in the
normal antibody repertoire [12–14]. Amyloidosis may then be
a consequence of a clonal expansion of a plasma cell producing
these specific light chains.
The reasons for the variability in organ distribution in systemic
AL-amyloidosis are not known. It is reasonable to believe that
variations are due to properties related to differences in protein
sequences. In addition to differences in properties in the individual
light chains, it has been suggested that there is a preferential organ
tropism for different variable light chain gene products [15,16].
Thus, AL lVI is significantly more often associated with clinically
important renal amyloidosis than other subtypes [15]. However,
the literature is sparse concerning the nature of the amyloid light
chain subgroup and distribution of amyloid in the body. This is in
a high degree true for amyloid of AL k type [16] although kI light
chains are particularly well represented in immunoglobulin light
chain sequences [14]. Moreover, performed studies are based on
clinical evaluation of effects of amyloid on the organ in whole.
Almost no studies on the structure of AL-proteins include any
detailed histological analyses, allowing comparisons on how
deposits are distributed in specific tissue structures. Finally, studies
in which both the AL-protein sequence and the tissue distribution
have been determined do not exist.
In the present study we have chosen to study four AL amyloid
proteins of kIb type (O18-O8) and, for comparison, four
amyloidogenic light chains of L2-L16 origin (k3a). We have
evaluated the distribution of amyloid deposits in the body from
available tissues, obtained at autopsy. The use of the material and
the study has been approved by the Ethical Committee of the
Uppsala University Hospital.
RESULTS
Comparison of the four AL-proteins of k1b type
The amino acid sequences of AL proteins Es305 and 366 have
been reported [17]. For details concerning amino acid sequencing
of AL 312 and AL 90, see supporting information (Text S1). The
four proteins belong to the kIb immunoglobulin light chain
subgroup and are derived from the O18-O8 gene, (Fig. 1). Most
amino acid differences are uncommon or unique. None of the four
kappa-1 light chains discussed here exhibit any of the three point
mutations that are highly correlated with amyloidosis among
kappa-1 light chains [14], i.e., Ile is found at position 29, Asp does
not appear at position 31, and the salt-bridge involving Arg61 and
Asp82 is intact in all of the proteins. On the other hand, two of the
light chain proteins, Es 305 and AL 366, [17], incorporate the
fourth ‘‘risk factor,’’ a glycosylation site.
The variable domains of these light chains have acidic pI values.
Es305 at 5.4 is the most basic, with 366, 312, and 90 pI values
Figure 1. Primary structure of the k1b and the k3a light chains compared with respective germline gene sequence. ---- No sequence : d, deletion,
UUU, end of the determined amino acid sequence.
doi:10.1371/journal.pone.0000981.g001
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replacements are over-represented in amyloidogenic kappa light
chains.However,Phe36(AL312)hasbeenseenin27otherkchains,
of which 16 were known to be associated with amyloidosis [10].
Each of the four kappa-1 sequences exhibits one unique amino
acid replacement: Thr13 (AL312), Met31 (AL90), Asn50 (Es305),
and Val95 (AL366) [10]. In addition, AL312 and AL366 have
a deletion at position 94. The rarity of these residue changes could
suggest that these are structurally unfavorable alterations and that
most kappa light chains that incorporate them do not become
a component of functional antibodies, a prerequisite for eventual
production by a neoplastic plasma cell. The uniqueness of Met31
and Val95 can also be explained by the fact that each of these
mutations requires two base changes. The remaining amino acid
replacements can be accomplished with single base changes.
Alternative amino acids that are observed at position 13 in
Framework 1 are hydrophobic, the presence of the hydroxyl group
in the Thr side chain (AL 312) may disrupt the hydrophobic core
of the beta domain. Position 50 is a highly promiscuous site in
CDR2, conceivably Asn50 (Es305) is highly destabilizing since all
other charged and neutral amino acids are observed among kappa
light chains. In such a case, the establishment of Es305 in a viable
antibody, eventually leading to the production of a neoplastic
plasma cell, could be the result of another somatic mutation in
Framework 1, i.e., the fortuitous occurrence of a stabilizing Leu for
Met replacement at position 4.
Comparison of the AL-proteins of k3a type
The four k3a AL-proteins were included in this study mainly for
comparison the deposition patterns between proteins of k1b and
k3a type. Since full amino acid sequences could not be obtained for
AL292 and AL324, no detailed molecular analysis was performed.
We anticipate that destabilizing amino acid replacements contrib-
ute to the development of amyloid fibrils by the k3a -proteins
studied here. Unsurprisingly, most of the amino acid changes were
innocuous and observed frequently as somatic mutations without
correlation with amyloidosis or were encoded by other germline
genes. The replacement of Met at position 4 is expected to improve
stability of AL324, indicating a significantly destabilizing mutation
at one or more other positions. One candidate is the replacement of
Thr by Asn at position 74. Although this would nominally be
considered an innocuous replacement, exchanging one small,
neutral amino acid for another, it has been found that introduction
of either asparagine or aspartic acid into a beta-strand is
destabilizing [18] with the impact of aspartic acid sufficient to
completely overcome the free energy of folding for the typical
variable light chain. Asn74 has been reported in three kappa light
chains, two from amyloidosis patients [17,19] and one from a light
chain deposition disease patient [20].
AL700 also appears to be structurally challenged. Gly at position
16 adds significant flexibility to an important beta turn and will be
destabilizing or impair the ability of the protein to fold. Replacement
of Arg24 by Trp would be expected to decrease the solubility of the
proteinand destabilizeit. Trp24 hasbeen documented inonekappa
light chain, a cryoglobulin [21].The replacement of Tyr86 by Phe,
often considered an exchange of similar amino acids is very
significant in this case. Tyr86 forms a so-called tyrosine corner [22].
In this case, it forms a buried hydrogen bond to the carbonyl of
Asp82, which itself forms a conserved salt-bridge with Arg61. So124
replaces Ser31 with Val. Although position 31 is highly variable
among light chain, introduction of Val at this position has been seen
in only two other kappa proteins. One formed amyloid [23] while
the other was associated with light chain deposition disease [24].
Comparable amino acids replacements of consequence are not
readily apparent in AL292 although several positions are missing
from the sequence.
Tissue distribution of AL k1b amyloid
The distribution of amyloid deposits in the four AL k1b patients is
given in Table 1. Since this is a retrospective study, not all organs
were available from the patients. Although all four individuals died
from their amyloid disease rather than from multiple myeloma, it
is obvious that the degree of amyloid infiltration varied highly, not
only between organs but also between patients. Patient 366 had
a very pronounced systemic amyloidosis with severe involvement
of many parts of the body including both parenchymatous and
non-parenchymatous organs. This is the only AL k1b patient with
notable deposits in the liver. Most remarkable was the very
pronounced gastrointestinal deposits in patients 312 and 90
(Fig. 2A). These were the main cause of death in patient 312. Also
patient 366 had fairly large amount of gastrointestinal amyloid
(Fig. 2B) but more as part of the severe systemic disease. Analysis
of specific tissue structures may be of particular interest concerning
a possibility of tissue affinity for individual light chains. Here can
be noted that the intestinal tunica muscularis propria was severely
affected in patients 312, 366 and 90 and moderately affected in
case Es305 while tunica muscularis mucosae was completely
spared in patients Es305 and 312, although topographically closely
situated and of similar cell constitution. In patients 366 and 90 on
the other hand, both layers contained amyloid.
Only the two patients 366 and 90 had splenic amyloid, in both
cases with sago distribution (Fig. 2C). The lack of amyloid in the
heart, except for minimal deposits in some vessels, in two of the
cases is remarkable. The two other individuals had pronounced
and diffuse myocardial deposits. Tongue amyloid was particularly
pronounced in patient Es305 (Fig. 2D).
Tissue distribution of AL k1b compared to AL k3a
amyloid
As seen from Table 1 there are conspicuous interindividual
variations in tissue distribution in both AL subgroups. Yet, there
are some striking differences between the two AL subgroups.
Pronounced parenchymal liver amyloidosis with hepatomegaly
was seen in all k3a patients but in none of the k1b individuals.
Also, glomerular involvement differed strongly between the two
subgroups. The complete lack of glomerular deposits in 3 of the
k1b patients contrasts against the pronounced infiltration in 3 of
the k3a cases (Fig. 2E and 2F). There were also tendencies to be
other deposition pattern differences between the two groups, e.g.
in the lung and in intestinal involvement. As seen in Table 1, the
patients with light chains derived from the k3a germline have
similar deposition pattern demonstrated as a severe systemic
amyloidosis affecting most organs investigated.
DISCUSSION
While much effort has been performed in order to understand
amyloidogenesis in general and fibrillogenesis in AL-amyloidosis,
very little has been done concerning factors important in tissue
localization of deposits. The remarkable variation in distribution of
amyloid deposits in systemic AL-amyloidosis has been noted in
many studies [6,25–29]. Differences in appearance and prognosis
between amyloidosis of AL k and AL l have sometimes been
suggested [16,30]. However, studies performed on association of
immunoglobulin light chain subgroups with organ manifestations
have mainly been based on clinical symptoms and no detailed
analyses of tissue involvement associated with specific light chain
gene products have been undertaken.
Deposition and AL-Amyloidosis
PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e981Occurrence of AL-amyloidosis is a consequence of a clonal
expansion of immunoglobulin light chain producing plasma cells
and a production of an amyloidogenic light chain. A very high
variability between different AL-proteins is obvious and finding
structural elements linked to tissue distribution of amyloid is
therefore extremely difficult. The present study is an effort to
partially overcome this problem. Four individuals with terminal
systemic AL-amyloidosis were studied and in whom the fibril
protein was of kIb type. Thus, the protein sequences were as
similar as can be obtained from different AL-proteins. However,
several differences between the four AL-proteins were evident and
these may influence both fibrillogenicity and tissue targeting.
One of the main aims of the present study was to analyze
whether AL-proteins from different individuals, where the mono-
clonal protein originated from the same VL gene showed any
obvious resemblance in amyloid deposition pattern. From Table 1
it is clear that the distribution of amyloid deposits varied highly
between the four patients in spite of the O18-O8 gene origin of the
light chains and the great sequence similarities. The most striking
and remarkable similarity was the lack of significant renal
Table 1. Distribution of amyloid in available Congo-red stained sections from the eight studied individuals with systemic AL
amyloidosis and in who the amyloid proteins were derived from the kI gene O18-O8 or the kIII gene L2-L16.
..................................................................................................................................................
Case (pI*) Es305 (5.36) 312 (4.68) 366 (4.09) 90 (4.4) 700 (9.8) So124 (9.7) 292 (N.D) 324 (N.D)
Lung
Alveoli + ++++ +++ - ++ +
Vessels + +++ +++ + + + ++
Heart
Myocardium - - +++ +++ +++ +++ ++ ++
Vessels + - +++ ++ ++ +++ ++ +++
Epicardium - + +++ ++ +++
Tongue ++++ +++ + ++ +++
Liver
Parenchyma - - ++ - ++++ ++++ ++++ ++++
Vessels + - +++ + ++ +++ ++ ++
Pancreas
Parenchyma - ++ ++ +++ +
Vessels + +++ ++ ++
Spleen
Parenchyma - ++ +++ ++++ ++++ ++++ ++++
Vessels - +++ +++ ++ +++ +++
Kidney
Glomeruli -** - + -** +++ ++++ ++++ +
Vessels - ++ + (+) ++ +++ ++ ++
Stomach
Mucosa - ++ + +
M.mucosae - - ++ -
Submucosa - ++ ++ +
M.propria ++ ++ ++ -
Ileum
Mucosa - - ++ + +++ +++ +++ ++
M.mucosae - - +++ ++ +++ +++ +++
Submucosa ++ + +++ ++ +++ ++ + +++
M.propria ++ ++++ +++ +++ - + - ++
Skin ++ - +
Dermis + ? ++
Subcutis
Adrenal cortex - + ++++ +++
Thyroid + + ++++ ++ ++++ ++ ++
Pituitary - +
Empty space, no tissue available; -, no amyloid; +, one or a few small amyloid deposits; ++, moderate amount of amyloid at several locations; +++, pronounced amyloid
deposits; ++++, more than 50% of the tissue replaced by amyloid.
*pI for the variable part of the light chain.
**Amyloid cast found in some tubular lumina.
doi:10.1371/journal.pone.0000981.t001
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PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e981involvement in any of the cases. It can be noted from Table 1 that
three out of four individuals with AL-protein of L2-L16 gene
origin had pronounced renal deposits, including glomeruli. The
calculated isoelectric points of the variable part of the four kappa-I
proteins were highly different from those of the two kappa-III
chains for which calculation was possible. Glomerular basement
membranes are rich in heparan sulfate proteoglycans and
therefore negatively charged. Light chains with high pI may
therefore be more easily trapped in glomeruli. This putative effect
of isoelectric points of the immunoglobulin light chains has to be
studied further. Presently, there is nothing known concerning
a possible effect of a single amino acid substitution on tissue
targeting. Although our study does not directly point to this
possibility, such effects may exist. The amino acid sequence
probably affects the deposition pattern since the light chains of the
k3a group are deposited in a more similar manner.
Glycosylation is among the identified risk factors for AL-
amyloidosis [10] and may also be important for determining in
which organs amyloid deposits occur. It has been suggested from
an experimental rat study that glycosylated immunoglobulin light
chains preferably deposit in the liver [31]. This was not verified in
the present study in which both glycosylated and nonglycosylated
k3a proteins formed heavy liver deposition.
A third possible important variable in the distribution of
amyloid, in addition to amino acid substitutions and glycosylation,
is the protein cleavage pattern and presence of constant region
peptides. Discussion of single amino acid substitutions and their
effects on properties such as isoelectric point of the variable domain
is relevant only if it is the full-length sequence that determines the
amyloidogenic properties of a light chain. Otherwise the very
complex cleavage patterns have to be taken into consideration.
Most AL-proteins are C-terminally truncated and lack a large piece
of the constant region. They are most often ragged, particularly C-
terminally but also to some part N-terminally. It is still unknown
whether truncation takes place before or after fibril formation but
cleavage has not been ruled out as an important event in
fibrillogenesis. The finding in this (data not shown) and some
earlier studies [32,33] have shown that in addition to the main N-
terminal fragment of a monoclonal light chain, AL-proteins often
contain small fragments of the constant region. This might indicate
that cleavage comes after fibrilformation. Occurrence of full-length
light chains in all deposits is in accordance with this assumption
although the possibility that deposits entrap light chains from the
circulation has not been ruled out. However, the situation may be
more complex since AL-proteins, mainly containing the constant
region have been described [3–5].
Figure 2. Demonstration of the variation in deposition pattern in the different organs. A. Cross-section of small intestine of AL312. The muscularis
propria is converted into amyloid masses (Am). The mucosa is indicated by arrows. B. Section from the stomach of AL Es305 showing large amounts
of amyloid between glands (Gl). C. Section of the spleen of AL90. Amyloid (Am) is seen distributed mainly in follicles. D. Section of the tongue of AL
Es305 showing large amounts of amyloid. Residual striated muscle fibers (arrows) are seen. E. Kidney section of AL90. The glomeruli (arrow) are
virtually free of amyloid. There is a tubular amyloid cast in the middle of the figure. F. Kidney section of AL Es305. The glomeruli (arrows) are free of
amyloid.
doi:10.1371/journal.pone.0000981.g002
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PLoS ONE | www.plosone.org 5 October 2007 | Issue 10 | e981AL amyloid is unique among the spectrum of amyloid diseases in
that it develops from the products of approximately 50 light chain
variable domain germline genes. As such, it might be considered to
represent some 50 different diseases, each with its own inherent
capability of preferential targeting of one or more organs or tissues.
However, as demonstrated in this report, patient-specific variations
of deposition are found in detailed pathological examination even
when the amyloidogenic light chain is derived from a single
germline gene. This property likely originates from somatic
mutations that occur naturally in light chains during the course
of immune system diversification. Although variability originating
from patient factors cannot be excluded, much less heterogeneity of
organ deposition is found in other systemic amyloidoses, which
usually originate from a single gene. We propose that each light
chain exhibits one or more determinants of organ-specificity, which
originate from primary structure and post-translational modifica-
tions. Eventual identification of such determinants could lead to
improved treatment of patients with AL amyloidosis, and has the
potential to contribute to the development of organ-specific drug
delivery systems relevant to many diseases.
MATERIALS AND METHODS
Patients
Tissue material from the eight individuals, who all died from
systemicAL-amyloidosisofk-type,wasavailableinthetissue bankof
the laboratory. The use of this material for protein studies has been
approved by the ethical committee of Uppsala University Hospital.
The nature of the material made it impossible to obtain consent
from the individuals or even relatives since some specimens are 30
years old. We therefore got permission (paragraph 257, Ups 01-
083) from the Ethical Committee at Uppsala University Hospital
to use this historical material for histological and protein studies
without individual consent.
Purification of amyloid fibril proteins
Amyloid-rich tissues (intestine in patient 312, pericardium in patient
366, liver in patient 292, tongue in patient Es305, thyroid in patient
90 and spleen inpatients 700, 324 and So124) were stored at 220uC
after the autopsy. Amyloid fibrils were extracted by repeated
homogenizations as described [34].The protein sequences of AL
366, AL Es 305, AL 700 and AL So124 have been described
previously [17,23,35,36]. Fibrils from AL 312, AL 292 and AL 90
were dissolved in 6 M guanidine HCl-Tris HCl buffer, pH 8.0,
containing 0.1 M dithiothreitol and the major fibril protein was
purified by repeated gel filtrations as described [37,38]. Pooled
fractions were dialyzed against distilled water and lyophilized.
Electrophoretic methods
Fibrils were dissolved in sample buffer containing 4% sodium
dodecylsulfate (SDS) and subjected to SDS-PAGE which was
performed as described [39].
Structural studies of AL 312
SDS-PAGE was run to evaluate the amyloid fibril protein fractions
[40]. Samples of the AL protein, as well as of pure tryptic peptides,
were hydrolyzed and analyzed by an automatic amino acid analyzer
(Applied Biosystems 421 A, Foster City, CA). Automatic Edman
degradation was performed using two different types of sequencers
(Applied Biosystems model 477A and Hewlett Packard, model 241).
The carboxymethylated amyloid fibril protein was digested with
trypsin and endoproteinase Asp-N [36]. Peptides were purified by
reverse phase high performance liquid chromatography (RP-HPLC)
as described [36]. Tryptic peptides were analyzed by the matrix
assistedlaserdesorption/ionizationtime-of-flightmassspectrometers
(MALDI TOF) Voyager-DE STR (Applied Biosystems) and Ettan
MALDI TOF (Amersham Biosciences) and by the hybrid instru-
ments quadrupole/ TOF LC MS/MS; QSTAR (Applied Biosys-
tems) and Q-Tof2 (Micromass UK Limited, Manchester, UK) and
the ion trap instrument LCQ DECA (Finnigan ThermoQuest,
London, UK). The companies kindly performed all mass analyses as
one of several test samples.
Structural studies of AL 90
Automatic Edman degradation of the purified protein was
performed for 47 cycles. The protein was digested with trypsin
and the resulting peptides were purified and sequenced by Edman
degradation as for AL protein 312.
Structural studies of AL 292 and AL 324
The extracted light chain proteins 292 and 324 were analyzed by
SDS-PAGE and visualized by Coomassie Brilliant Blue. Appro-
priate bands were excised and treated for in-gel digestion as
described [41]. Briefly, the dye was extracted and the gel pieces
were equilibrated with ammonium bicarbonate, then dried, and
a solution of porcine modified trypsin was allowed to soak into the
gel. After overnight incubation, the generated peptides were
analyzed by Peptide Mass Fingerprinting on an Ultraflex MALDI
TOF/TOF instrument from Bruker, Bremen, Germany. The
instruments settings were optimized for analytes up to 4000 Da
and the matrix was alfa-cyano 4 –hydroxy cinnamic acid. To
improve amino acid sequencing using Post Source Decay, the
digest was N-terminally sulfonated using the CAF-MALDI
Sequencing kit from GE Healthcare, Uppsala, Sweden [42].
Peptides were then fragmented in the LIFT mode. Sequences were
manually interpreted. Fibril material of AL 292 was also dissolved
in 6 M guanidine HCl as described [3] and separated on
a Sepharose 6B-CL gel filtration column. Pooled fractions were
further analyzed by Edman degradation for 14 cycles and thereby
the first 14 amino acid residues of AL 292 could be confirmed.
SUPPORTING INFORMATION
Text S1
Found at: doi:10.1371/journal.pone.0000981.s001 (0.03 MB
DOC)
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